BiotechTube

CT-P42 + Eylea

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetic Macular Edema (DME)

Conditions

Diabetic Macular Edema (DME)

Trial Timeline

Jul 22, 2021 → Apr 24, 2023

NCT ID
NCT04739306

About CT-P42 + Eylea

CT-P42 + Eylea is a phase 3 stage product being developed by Celltrion for Diabetic Macular Edema (DME). The current trial status is completed. This product is registered under clinical trial identifier NCT04739306. Target conditions include Diabetic Macular Edema (DME).

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Macular Edema (DME) were approved

Approved (20) Terminated (3) Active (0)
✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
✅Anplag(Sarpogrelate) + PlaceboYuhanApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved
✅duloxetine hydrochlorideEli LillyApproved
✅DuloxetineEli LillyApproved
✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04739306Phase 3Completed

Competing Products

20 competing products in Diabetic Macular Edema (DME)

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CHF6467 activeComac MedicalPhase 1/2
22
Ruboxistaurin mesylateEli LillyPhase 3
40
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
Baricitinib + PlaceboEli LillyPhase 2
35
LY3857210 + PlaceboEli LillyPhase 2
35
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
43
Anplag(Sarpogrelate) + PlaceboYuhanApproved
43
CS-3150 + placeboDaiichi SankyoPhase 2
35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3
40
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Beraprost sodiumAstellas PharmaPre-clinical
22
ASP8825 + PlaceboAstellas PharmaPhase 2
27